KalVista Pharmaceuticals, Inc.
KALV
$13.55
-$0.05-0.37%
NASDAQ
| 01/31/2025 | 10/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -24.18% | -37.59% | |||
| Gross Profit | 24.18% | 37.59% | |||
| SG&A Expenses | 3.92% | 65.91% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -6.27% | 3.61% | |||
| Operating Income | 6.27% | -3.61% | |||
| Income Before Tax | -4.72% | -4.51% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -14.77% | -4.51% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -14.77% | -4.51% | |||
| EBIT | 6.27% | -3.61% | |||
| EBITDA | 6.30% | -3.62% | |||
| EPS Basic | -1.80% | -3.48% | |||
| Normalized Basic EPS | 8.04% | -4.25% | |||
| EPS Diluted | -1.80% | -3.48% | |||
| Normalized Diluted EPS | 8.04% | -4.25% | |||
| Average Basic Shares Outstanding | 12.73% | 1.00% | |||
| Average Diluted Shares Outstanding | 12.73% | 1.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||